Zobrazeno 1 - 3
of 3
pro vyhledávání: '"M Del Barrio Aranda"'
Autor:
M Gajardo Álvarez, R Tamayo Bermejo, M Del Barrio Aranda, J González Chávez, A Linares Alarcón
Publikováno v:
European Journal of Hospital Pharmacy. 22:A16.2-A16
Background The new combination tenofovir/emtricitabine/rilpivirine (TDF/FTC/RPV) produces fewer adverse central nervous system effects, encouraging better adherence while being as effective as the tenofovir/emtricitabine/efavirenz (TDF/FTC/EFV) combi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6586771440b25550283f7636dc2fa399
https://doi.org/10.1136/ejhpharm-2015-000639.38
https://doi.org/10.1136/ejhpharm-2015-000639.38
Publikováno v:
European Journal of Hospital Pharmacy. 20:A120.1-A120
Background Lung cancer is the most common malignancy in the world, with approximately 1.4 million new cases per year, representing 16.6% of all tumours in men and 7.5% in women. It is the leading cause of cancer death. According to the European Medic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c3f03eb4cda67c31aeec59790b6f1cd3
https://doi.org/10.1136/ejhpharm-2013-000276.332
https://doi.org/10.1136/ejhpharm-2013-000276.332
Autor:
E. Valverde Alcalá, I Muñoz Castillo, E. Valverde Molina, C. Andrés González, M Del Barrio Aranda
Publikováno v:
European Journal of Hospital Pharmacy. 19:127.1-127
Background Adalimumab and etanercept are both anti-TNF drugs used to treat various autoimmune pathologies. Purpose The purpose of this study was to evaluate the use of adalimumab and etanercept in authorised and unauthorised indications (off label us
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a2fef17292f489b166d796aa785b37c2
https://doi.org/10.1136/ejhpharm-2012-000074.111
https://doi.org/10.1136/ejhpharm-2012-000074.111